m 2 /day) with concurrent radiotherapy (50.4 gray in 28 fractions over 5.5 weeks).
Clinical benefit response of concurrent chemoradiotherapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer
β Scribed by Takuji Okusaka; Shuichi Okada; Hiroshi Ishii; Hidekazu Nakasuka; Hiroyasu Nagahama; Masayoshi Yoshimori; Minako Sumi; Kouichi Tokuuye; Yoshikazu Kagami; Hiroshi Ikeda
- Publisher
- Springer
- Year
- 1998
- Tongue
- English
- Weight
- 422 KB
- Volume
- 3
- Category
- Article
- ISSN
- 1341-9625
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Chemoradiotherapy is widely used for patients with locally advanced pancreatic carcinoma. The purpose of this study was to clarify the efficacy and feasibility of chemoradiotherapy with more intensive radiotherapy in these patients, using a combination of intraoperative r
## Abstract ## Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5βfluorouracil (5βFU) and cisplatin has increased acute toxicities as well as survival. Onceβweekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we